UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 5, 2014

MOLINA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

200 Oceangate, Suite 100, Long Beach, California 90802

(Address of principal executive offices)

Registrant’s telephone number, including area code: (562) 435-3666

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Item 1.01 Entry into a Material Definitive Agreement

On September 5, 2014, Molina Healthcare, Inc., a Delaware corporation (the “Company”), entered into an indenture, dated as of September 5, 2014, with U.S. Bank National Association, as trustee (the “Indenture”), pursuant to which the Company issued its 1.625% Convertible Senior Notes due 2044 (the “2044 Notes”). Additional information pertaining to the 2044 Notes and the Indenture is contained in Item 2.03 and incorporated herein by this reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant

On September 5, 2014 (the “Settlement Date”), in exchange for an aggregate principal amount of $176.551 million of the Company’s 3.75% Convertible Senior Notes due 2014 (the “Existing Notes”), the Company issued 2044 Notes in the aggregate principal amount of $176.551 million and an aggregate of 1,683,925 shares of the Company’s common stock (“Exchange Shares”), and paid cash in the approximate amount of $3.3 million (which cash amount equals the accrued and unpaid interest on the Existing Notes exchanged up to, but excluding, the Settlement Date plus the amount of interest that would have been payable on such Existing Notes had such Existing Notes remained outstanding until October 1, 2014) in exchange for Existing Notes (the “Exchange”).

The 2044 Notes are the Company’s senior unsecured obligations and rank senior in right of payment to any of the Company’s indebtedness that is expressly subordinated in right of payment to the 2044 Notes; equal in right of payment to any of the Company’s unsecured indebtedness that is not subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of the Company’s subsidiaries.

The 2044 Notes will mature on August 15, 2044 and will bear interest at a rate of 1.625% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on February 15, 2015. The Company will pay additional interest, if any, (i) at a rate per annum equal to 0.25% on each $1,000 principal amount of the 2044 Notes on each interest payment date for which the aggregate principal amount of the 2044 Notes outstanding was less than $100 million as of the close of business on the regular record date corresponding to such interest payment date and (ii) at its election, as the sole remedy relating to the failure to comply with certain of its reporting obligations under the Indenture at a rate per annum equal to 0.25% (or, under certain circumstances, 0.50%) of the outstanding principal amount of the 2044 Notes. In addition, beginning with the semiannual interest period commencing immediately following the interest payment date on August 15, 2018, contingent interest will accrue on the 2044 Notes during any semiannual interest period in which certain conditions are satisfied. The Company will also pay contingent interest equal to any extraordinary cash dividend or distribution paid to all or substantially all holders of the Company’s common stock that the Company’s board of directors designates as payable with respect to the 2044 Notes.

Holders of 2044 Notes may convert their 2044 Notes at their option at any time prior to the close of business on the business day immediately preceding February 15, 2044 only under certain

-1-

limited circumstances. On or after February 15, 2044 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2044 Notes at any time, regardless of the circumstances. Upon conversion, the Company will pay cash and, if applicable, deliver shares of the Company’s common stock to the converting holder in an amount per $1,000 principal amount of 2044 Notes equal to the settlement amount (as defined in the Indenture).

The conversion rate will initially be 17.2157 shares of common stock per $1,000 principal amount of 2044 Notes (equivalent to an initial conversion price of approximately $58.09 per share of common stock). The initial conversion rate is based on a conversion premium of approximately 30% above the arithmetic average of the daily volume weighted average prices of the Company’s common stock as published on Bloomberg page “MOH <equity> AQR” over the 10 trading day period beginning on, and including, August 19, 2014.

The Company may not redeem the 2044 Notes prior to August 19, 2018. On or after August 19, 2018, the Company may redeem for cash all or part of the 2044 Notes, except for the 2044 Notes that the Company is required to repurchase in connection with a fundamental change (as defined in the Indenture) or on any specified repurchase date (as defined in the Indenture). The redemption price for the 2044 Notes will equal 100% of the principal amount of the 2044 Notes being redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

If the Company undergoes a fundamental change (as defined in the Indenture), holders of 2044 Notes may require the Company to repurchase for cash all or part of their 2044 Notes at a repurchase price equal to 100% of the principal amount of the 2044 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. Also, holders of 2044 Notes may require the Company to repurchase some or all of the 2044 Notes for cash on August 19, 2018, August 19, 2024, August 19, 2029, August 19, 2034 and August 19, 2039, in each case, at a specified date repurchase price equal to 100% of the principal amount of the 2044 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the specified repurchase date.

Under the Indenture, certain events are considered “Events of Default,” which may result in the acceleration of the maturity of the 2044 Notes, including:

-2-

The foregoing descriptions of the Indenture and the 2044 Notes do not purport to be complete and are qualified in their entirety by reference to the Indenture and the form of 2044 Notes, which are filed as Exhibits 4.1 and 4.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities

Issuance of 2044 Notes and Exchange Shares in the Exchange

On September 5, 2014, the Company issued 2044 Notes in the aggregate principal amount of $176.551 million and an aggregate of 1,683,925 Exchange Shares, and paid cash in the approximate amount of $3.3 million (which cash amount equals the accrued and unpaid interest on the Existing Notes exchanged up to, but excluding, September 5, 2014 plus the amount of interest that would have been payable on such Existing Notes had such Existing Notes remained outstanding until October 1, 2014) in exchange for Existing Notes in the aggregate principal amount of $176.551 million. The 2044 Notes and Exchange Shares were issued pursuant to an

-3-

exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Neither the Company nor any person acting on its behalf offered the 2044 Notes or the Exchange Shares by any form of general solicitation or general advertising, and each person who participated in the Exchange represented that it is an accredited investor (within the meaning of Rule 501 promulgated under the Securities Act) and a qualified institutional buyer (as defined in Rule 144A under the Securities Act). The Company did not receive any proceeds from the issuance of the 2044 Notes and the Exchange Shares.

Upon conversion of the 2044 Notes, the Company will pay cash and, if applicable, deliver to the converting holder a number of shares of the Company’s common stock per $1,000 principal amount of 2044 Notes equal to the settlement amount (as defined in the Indenture).

Additional information pertaining to the Exchange is contained in Items 1.01 and 2.03 of this Current Report on Form 8-K and incorporated herein by reference.

The 2044 Notes, any shares of common stock issuable upon conversion of the 2044 Notes and the Exchange Shares have not been, and will not be, registered under the Securities Act or any state securities law. The Company does not intend to file a shelf registration statement for resale of the 2044 Notes, the shares of the common stock, if any, issuable upon conversion thereof or the Exchange Shares.

Issuance of Company Common Stock for Services Rendered

On September 5, 2014, the Company issued 80,958 shares of the Company’s restricted common stock to J. Wood Capital Advisors LLC (“JWCA”) for services rendered in connection with the Exchange. The shares were issued pursuant to an exemption provided by Section 4(a)(2) of the Securities Act. JWCA represented to the Company that it is an accredited investor (within the meaning of Rule 501 promulgated under the Securities Act), and neither the Company nor any person acting on its behalf offered the shares by any form of general solicitation or advertising. The Company did not receive any proceeds from the issuance of the shares.

This Current Report on Form 8-K does not constitute an offer to sell, or a solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering would be unlawful.

Item 9.01 Financial Statements and Exhibits

-4-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

-5-

EXHIBIT INDEX